Evidence map›Paper›PMID 42677835›Full record

ArticleThe Journal of clinical investigation2026

An NFATC4 phospho-switch links matrix stiffness to fibroblast fate.

Rebecca Shelley Frabotta, Purushothama Rao Tata

Abstract readComment
In one paragraph

Article in The Journal of clinical investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Rebecca Shelley FrabottaDepartment of Cell Biology, Duke University School of Medicine, Durham, North Carolina, USA.
Purushothama Rao TataDepartment of Cell Biology, Duke University School of Medicine, Durham, North Carolina, USA.

Funding

Molecular control of a novel transitional cell state in alveolar regenerationR01HL153375 · NHLBI · DUKE UNIVERSITY · PI Purushothama Rao Tata · 2020 to 2026
$3.4M
Cellular crosstalk and molecular mechanisms in the initiation and progression of pulmonary fibrosisR01HL160939 · NHLBI · DUKE UNIVERSITY · PI TATA, PURUSHOTHAMA RAO · 2022 to 2025
$2.1M
Mechanisms of submucosal gland cell mediated airway regenerationR01HL146557 · NHLBI · DUKE UNIVERSITY · PI TATA, PURUSHOTHAMA RAO · 2019 to 2023
$2.0M
NHLBI NIH HHS R01 HL146557NHLBI NIH HHS R01 HL153375NHLBI NIH HHS R01 HL160939
6 · The paper itself

Abstract

Fibrosis is driven by the activation of quiescent fibroblasts into contractile, matrix-secreting myofibroblasts, a transition governed jointly by biochemical signals and by the mechanical properties of the ECM. How the physical stiffness of tissue is converted into a durable transcriptional cell fate decision has remained poorly understood. In this issue of the JCI, Kadri et al. used global phosphoproteomic profiling of primary human lung fibroblasts across a defined stiffness gradient to identify phosphorylation of NFATC4 at residues S213/S217 as a mechanosensitive switch that is both necessary and sufficient for the fibroblast-to-myofibroblast transition. They validated these predictions in an independent transcriptomic dataset from patients with idiopathic pulmonary fibrosis, showing that NFATC4 expression increased with disease severity. Prior work has implicated NFATC4 activation in cardiac and hepatic fibrosis, suggesting that this single modification may serve as a convergence point for mechanical and cytokine signals across fibrotic diseases.

Indexed as

Extracellular MatrixFibroblastsIdiopathic Pulmonary FibrosisMyofibroblastsNFATC Transcription FactorsAnimalsHumansMechanotransduction, CellularPhosphorylationNFATC Transcription Factors

Identifiers

PMID42677835
PMCPMC13528932

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.